Background
==========

The passive immunity transferred to newborns in a number of animal species through ingestion of mother's colostrum or milk demonstrates the important biological role played by oral immunoglobulins.[@b1-ceg-9-365] Bovine serum is similarly rich in antibodies and contains up to 25 mg of immunoglobulins per milliliter -- the majority of which is in the form of immunoglobulin G (IgG).[@b1-ceg-9-365],[@b2-ceg-9-365] Numerous studies in young animals have demonstrated that oral administration of bovine plasma- or serum-derived protein concentrates, which contain high levels of these immunoglobulins, leads to improvements in appetite, weight gain, intestinal growth, and gut barrier function.[@b3-ceg-9-365],[@b4-ceg-9-365] More recently, there has been increasing interest in the use of such immunoglobulin-containing protein isolates from bovine plasma or serum in human beings at risk for certain intestinal disorders or to help manage chronic conditions affecting the gastrointestinal (GI) tract.

The beneficial effects of orally administered immunoglobulins depend upon the passage of these proteins through the stomach and into the lumen of the lower GI tract. During this transit, it is presumed that these proteins are resistant to degradation by gastric acid, pepsin, and pancreatic and small intestinal digestion enzymes as well as proteolytic enzymes released by the colonic microflora. Results from a number of studies in human beings indicate that significant amounts of orally administered immunoglobulins retain antigen-neutralizing activity along the GI tract, based on the recovery of intact and immunologically active IgG in ileal contents and feces.[@b5-ceg-9-365]--[@b8-ceg-9-365]

Serum-derived bovine immunoglobulin/protein isolate (SBI) is the primary ingredient in a novel medical food (EnteraGam^®^) being evaluated in a number of GI disorders. SBI is composed of ≥90% pure protein with significant amounts of essential amino acids ([Table 1](#t1-ceg-9-365){ref-type="table"}). Over half of the protein content is in the form of immunoglobulins in which IgG constitutes the major isotype or class. The product also contains other proteins and peptides that reflect the composition of plasma and are similar to serum proteins found in colostrum and milk but does not contain casein, whey, or lactose.[@b9-ceg-9-365] Studies in animals and human beings provide evidence that SBI is safe, improves nutritional status, has positive effects on various biomarkers of intestinal disease, and benefits patients with inflammatory bowel disease (IBD), irritable bowel syndrome with diarrhea (IBS-D), or human immunodeficiency virus (HIV)-associated enteropathy.[@b10-ceg-9-365],[@b11-ceg-9-365]

The purpose of the current study was to evaluate the absorption and safety of SBI in normal, healthy adult volunteers. Overall absorption was assessed by measuring the increase in amino acids in the blood following a single administration of one of three doses (5 g, 10 g, or 20 g) of SBI. Stool specimens from each subject were analyzed for the presence of bovine IgG prior to and after ingestion of SBI up to 14 days. The safety of the product was evaluated by recording adverse events (AEs) and testing for the presence of bovine IgG in the blood.

Methods
=======

Study population
----------------

Male and nonpregnant female adult volunteers aged ≥18 years who had a body mass index of ≥18 kg/m^2^ and ≤32 kg/m^2^ with no history of allergy to beef or any ingredient in SBI were considered eligible for the study. The volunteers were also in good health and physical condition as determined by medical history and clinical laboratory tests prior to study commencement. The laboratory tests included serum creatinine, blood urea nitrogen, pre-albumin, albumin, glucose, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total bilirubin, electrolytes (Na^+^, K^+^, and Cl^−^), calcium, cholesterol, low-density lipoprotein, high-density lipoprotein and triglycerides, complete blood count (hemoglobin, hematocrit, red blood cell count, white blood cell count with differential, and platelet), and urinalysis (pH, ketones, blood, glucose, protein). Volunteers who had positive test results for HIV or hepatitis B or C were excluded from participation. Volunteers who participated in another investigational study 30 days or donated blood 7 days prior to study commencement, were unable to comprehend or comply with the study protocol, and were unable to give informed consent were excluded as well.

Study design
------------

This prospective outpatient study was composed of two phases: a double-blind phase and an open-label phase ([Figure 1](#f1-ceg-9-365){ref-type="fig"}). The double-blind phase was a randomized, placebo-controlled, crossover design to evaluate the concentration of bovine IgG in plasma following the oral administration of SBI, amino acid profile, and safety parameters. The doses of SBI were selected from two human trials that demonstrated improvement in GI symptoms in patients with IBS-D (5 g/day and 10 g/day) or patients with HIV-associated enteropathy (5 g/day).[@b10-ceg-9-365],[@b11-ceg-9-365] A total daily dose of 20 g of SBI was included in the present study for further evaluation of safety. Subjects were required to fast overnight (≥8 hours) prior to arriving at the clinic on day 1 when they were randomized to receive either placebo (dextrose) or EnteraGam (each packet contained 5 g of SBI, dextrose, and a trace amount of sunflower lecithin) dissolved in 240 mL of water at an SBI dose level of 5 g, 10 g, or 20 g. Subjects were not allowed to consume water 1 hour before or 1 hour after administration of the investigational product (dextrose or EnteraGam); food was not allowed for at least 3 hours following the administration. The process was repeated for day 2 with another overnight fast (≥8 hours), followed by oral administration of the matching dose of the investigational product not received the previous day (ie, subjects who received 5 g, 10 g, or 20 g of SBI on day 1 received the matching dose of placebo on day 2, and subjects who received 5 g, 10 g, or 20 g of placebo on day 1 received the matching dose of SBI on day 2). Serial blood samples for amino acid analysis were collected on day 1 and day 2 immediately before (time 0) and at 15 minutes, 30 minutes, 45 minutes, 60 minutes, 90 minutes, 120 minutes, and 180 minutes after administration of the investigational product. Blood samples for the assessment of bovine IgG were collected immediately before and 90 minutes following administration of the investigational product on day 1 and day 2. A baseline stool sample was collected prior to dosing on day 1; if the sample could not be collected on day 1, then it was provided by the subject on day 2. Vital signs (blood pressure, heart rate, and oral temperature) were monitored at the screening visit, check-in on day 1 and day 2, and 3 hours following administration of the investigational product on day 1 and day 2.

The open-label phase of the study included BID dosing of EnteraGam for 14 days (through study day 16) to further evaluate the safety parameters and digestibility of bovine IgG. All the subjects initiated an open-label dosing of SBI on day 3. Subjects were instructed to consume divided portions of the SBI dose BID in 120 mL of water or noncaloric flavored water (ie, 2.5 g BID; 5 g BID; and 10 g BID). A single blood sample for the assessment of bovine IgG after multiple doses was collected on day 16. Additional stool samples for the assessment of bovine IgG were collected on day 9 and day 16 (end of the study). Safety monitoring was performed throughout the study.

Amino acid analysis
-------------------

Plasma amino acid analysis was conducted by liquid chromatography--electrospray-tandem mass spectrometry (LC--ESI-MS/MS) using an Agilent 1200/6460 Triple-Quadrupole LC/MS system (Santa Clara, CA, USA). Standards and 25 µL of plasma were processed using an EZ:faast™ (Phenomenex, Torrance, CA, USA) analysis kit for analyzing physiological amino acids by LC--MS.[@b12-ceg-9-365]

Amino acids quantified include all of those contained in SBI ([Table 1](#t1-ceg-9-365){ref-type="table"}) along with citrulline and ornithine. Blood samples for amino acid analysis were taken immediately before (time 0) and at 15 minutes, 30 minutes, 45 minutes, 60 minutes, 90 minutes, 120 minutes, and 180 minutes following administration of the investigational product.

Detection of bovine IgG in plasma and stool
-------------------------------------------

Plasma samples were tested for bovine IgG content using a commercially available enzyme-linked immunosorbent assay (ELISA) kit with a sheep polyclonal antibody that specifically reacts to bovine IgG heavy chain (ELISA; Kit E11-118; Bethyl Laboratories, Inc., Montgomery, TX, USA). Bovine IgG was quantified in human plasma samples with minor modifications according to the manufacturer's instructions. A standard curve was generated by the addition of known concentrations of lyophilized bovine IgG (product \#I5506; Sigma-Aldrich, St. Louis, MO, USA) to commercially available normal human plasma (product \#23D00; SeraCare Life Sciences, Milford, MA, USA). All standards and samples were diluted (1:5) in a standard dilution buffer prior to the assay. The reaction time of 3,3′,5,5′-tetramethylbenzidine with samples and standards was increased from 30 minutes to 60 minutes, which improved the absorbance range across the standard curve. Preliminary experiments with the modified assay established that the limit of quantification (LOQ) of bovine IgG in diluted plasma samples was 3.8 ng/mL (ELISA kit lot \#140821) and 4.6 ng/mL (ELISA kit lot \#140605).

Stool samples were divided into two portions: one aliquot was processed to determine the bovine IgG content and the other aliquot was immediately frozen and stored at −80°C. The frozen stool aliquot was subsequently processed to determine fecal dry weight by measuring \~1 g of the stool, which was transferred to a drying oven and maintained at 120°C until no change in sample weight was observed over a 24-hour period. The remaining sample was weighed and recorded as sample fecal dry weight. For the analysis of bovine IgG, \~1 g of stool sample was mixed with 5 mL of cold Tris-buffered saline, vortexed for 1 minute, and homogenized for 30 seconds using an Omni Tissue Homogenizer with a clean, disposable Hard Tissue Omni Tip™ Plastic Homogenizing Probes (7 mm × 110 mm). Homogenized samples were then centrifuged at 4°C, 1500× *g* for 15 minutes to pellet remaining solids in the stool samples before harvesting the supernatant, which was stored at −70°C until shipped on dry ice for analysis. Bovine IgG in stool samples was quantified by a custom-developed ELISA utilizing a goat polyclonal antibody that specifically reacts to bovine IgG heavy and light chains with minimum reactivity to human, mouse, and rat (Bethyl Laboratories, Inc.). Preliminary experiments with the custom assay established that the LOQ of bovine IgG in human stool homogenate was 2.7 pg/mg dry weight.

Safety assessment
-----------------

The safety of SBI was evaluated in all subjects who consumed at least one packet of the investigational product. It was assessed by conducting physical examinations, evaluating vital signs, performing clinical laboratory testing, and monitoring AEs following oral administration of SBI. AEs were coded using the MedDRA coding dictionary and monitored for all subjects from the time of study initiation (informed consent) through the last administration of the investigational product. Therapy-emergent AEs (TEAE) were defined as any event with a start date occurring on or after first dose date of the investigational product or, if preexisting, worsening after first dose date of the investigational product. The study investigator was solely responsible for determining the relationship of an AE with the investigational product based on all the available information at the time of event recording, including any preexisting medical condition(s).

A physical examination, including a comprehensive chemistry panel, complete blood count with differential, and urinalysis, was performed during the screening visit. Chemistry and hematology laboratory parameters were repeated at the end of the study visit (day 16). Symptom-directed physical examinations were performed at the study visits (ie, days 1, 2, 9, and 16) and for unscheduled clinic visits as needed. Subject-reported concomitant medications taken during the study were recorded at each visit.

Statistical methods
-------------------

Following a single administration of SBI (5 g, 10 g, or 20 g) or placebo, plasma amino acid levels were quantitated as described earlier. Differences between the SBI dose groups and placebo were analyzed by comparing *C*~max~ and area under the curve (AUC) from 0 minutes to 180 minutes (AUC~0--180~). The *C*~max~ and AUC were estimated using the post-administration amino acid responses over a 3-hour sampling interval and analyzed using a mixed model analysis of covariance (ANCOVA) technique appropriate for a two-period crossover design. A 95% confidence interval and the associated *p*-value for the least square (LS) means between the SBI groups (test) and placebo were provided for the amino acid response profiles. One subject from the 20 g group was excluded from the amino acid analysis due to protocol deviation. A sensitivity analysis was also conducted across participant response data within group, where data flagged as possible "outliers" were excluded from subsequent analyses. The method for outlier detection used a robust regression, leverage-point detection analysis, identifying outliers as data points with a projected Mahalanobis distance \>2.

Differences in the mean change of stool bovine IgG concentrations between test doses of SBI (2.5 g BID; 5 g BID; 10 g BID) collected at day 9 and day 16 and corresponding baseline were analyzed using a mixed covariate-adjusted model for paired data approach.

Baseline for all efficacy and safety variables was defined as the procedure performed during the screening visit or pre-dose on day 1, whichever provided the last pre-therapy assessment.

All statistical analyses were performed using SAS^®^ Version 9.3. Except where noted, all statistical tests were two sided and performed at an alpha value of 0.05 significance. No corrections of multiple testing were performed, and *p*-values were rounded to four decimal places.

Ethics, consent, and permissions
--------------------------------

The research protocol was approved by the Schulman Associates Institutional Review Board, Inc. (protocol ID: EH4001). Eligible participants were enrolled in the study after collecting written informed consent. This study was also registered with [ClinicalTrials.gov](http://ClinicalTrials.gov) (NCT02017405) on December 10, 2013.

Results
=======

Subject disposition and demographics
------------------------------------

A total of 47 individuals were screened in this study, of whom 42 subjects were enrolled and randomized at two study sites in NC, USA, between November 2013 and March 2014. One subject withdrew consent after a single 20 g placebo dose on day 1, leaving a total of 41 subjects who received SBI (5 g, n=18; 10 g, n=12; 20 g, n=11) during the double-blind (crossover) phase ([Table 2](#t2-ceg-9-365){ref-type="table"}). Dosing errors occurred in a total of six subjects at one site during this phase of the study. Specifically, four subjects assigned to receive 10 g SBI received 5 g SBI instead and two subjects assigned to receive 20 g SBI actually received 10 g SBI. Each of these subjects continued with the assigned dose of SBI during the 14-day, open-label phase of the study. As a result, six new subjects were added to the double-blind phase to ensurê12 subjects per SBI group. A total of 38 of the 41 subjects were \>80% compliant with the investigational product during the open-label phase. Baseline demographics of the subjects were comparable across the SBI groups ([Table 3](#t3-ceg-9-365){ref-type="table"}). The mean age of the healthy subjects was 40.2 years; 55% were male and 59% were White.

Plasma amino acid profile after ingestion of SBI
------------------------------------------------

The postprandial absorption of the protein within SBI was assessed following an overnight fast by measuring plasma concentrations of amino acids after a single administration of one of three doses (5 g, 10 g, or 20 g). As shown in [Figure 2](#f2-ceg-9-365){ref-type="fig"}, the calculated AUC~0--180~ for both total ([Figure 2A](#f2-ceg-9-365){ref-type="fig"}) and essential ([Figure 2B](#f2-ceg-9-365){ref-type="fig"}) amino acids following overnight fasting increased as the amount of SBI ingested was increased from 5 g to 20 g. The calculated AUC~0--180~ for total amino acids following the ingestion of a single dose of 5 g, 10 g, or 20 g of SBI was 15.61 mmol/mL×min, 45.14 mmol/mL×min, and 107.18 mmol/mL×min, respectively. The calculated AUC~0--180~ for essential amino acids following the ingestion of a single dose of 5 g, 10 g, or 20 g of SBI was 14.89 mmol/mL×min, 26.92 mmol/mL×min, and 47.53 mmol/mL×min, respectively. The AUC~0--180~ for tryptophan ([Figure 2C](#f2-ceg-9-365){ref-type="fig"}) was 1.12 mmol/mL×min, 3.08 mmol/mL×min, and 3.74 mmol/mL×min for the 5 g, 10 g, or 20 g dose of SBI, respectively. Statistical analysis of these AUC data revealed that, for each dose of SBI, there was a significant (*p*\<0.02) amount of amino acid absorption in terms of essential amino acids when compared to the placebo group. Absorption of total amino acids was statistically significant (*p*\<0.02) at the 10 g and 20 g doses of SBI but not at the lowest dose. In terms of the individual amino acids quantified, some showed the same statistically significant difference over placebo with increasing SBI dose while others did not. Absorption of the essential amino acid tryptophan was statistically significant (*p*\<0.02) for each dose of SBI administered ([Figure 2C](#f2-ceg-9-365){ref-type="fig"}).

The plasma amino acid concentration-time curve plots depicting amino acid absorption and used for calculation of AUC (0--180 min) values are shown in [Figure 3](#f3-ceg-9-365){ref-type="fig"}. Following the ingestion of SBI, an increase in total and essential amino acids was observed in all SBI groups with peak plasma concentrations appearing at 30--45 minutes for the lower doses (ie, 5 g and 10 g), but delayed until 60--120 minutes for the 20 g group. The peak concentration (LS mean *C*~max~) for total amino acids following the ingestion of a single dose of 5 g, 10 g, or 20 g of SBI was 3.38 mmol/min, 3.58 mmol/min, and 3.54 mmol/min, respectively. The peak LS mean *C*~max~ for essential amino acids following the ingestion of a single dose of 5 g, 10 g, or 20 g of SBI was 1.19 mmol/min, 1.34 mmol/min, and 1.34 mmol/min, respectively. Plasma concentrations of tryptophan followed a similar profile with increasing doses of SBI resulting in longer times to peak concentration. In addition, plasma tryptophan levels remained above baseline through 180 minutes following the 20 g dose of SBI (*p*\<0.01) but returned to baseline earlier in the 5 g and 10 g SBI groups. Tryptophan peak LS mean *C*~max~ following the ingestion of a single dose of 5 g, 10 g, or 20 g of SBI was 0.08 mmol/min, 0.10 mmol/min, and 0.10 mmol/min, respectively.

Bovine IgG in stool
-------------------

To determine the extent to which the IgG component of SBI is degraded chemically and/or enzymatically during transit through the GI tract, stool samples collected at day 1 (baseline), day 9, and at the end of the study (day 16) were tested for the presence of bovine IgG. When compared to baseline samples, significantly higher amounts of bovine IgG were detected in stool samples obtained on day 9 for subjects ingesting SBI daily at levels of 5 g (103.8 pg/mg, *p*\<0.02), 10 g (139.2 pg/mg, *p*\<0.004), and 20 g (146.7 pg/mg, *p*\<0.0003). Similar results were obtained on day 16 following the daily ingestion of SBI at levels of 5 g (100.79 pg/mg, *p*\<0.02), 10 g (160.20 pg/mg, *p*\<0.002), and 20 g (111.59 pg/mg, *p*\<0.003). These results confirm that bovine IgG is capable of surviving the passage through the entirety of the GI tract.

Safety
------

The "safety population" consisted of randomized subjects who received at least one dose of the investigational product. An overall summary of subjects reporting TEAEs is presented in [Table 4](#t4-ceg-9-365){ref-type="table"}. A total of 20 subjects experienced an AE during the study. These AEs were judged by the investigator as mild or moderate in intensity with no severe AEs or serious AEs (SAEs) reported. The number of subjects reporting TEAEs at an incidence of \>2% during the study included: abdominal cramps (four), constipation (three), bloating (two), diarrhea (two), flatulence (two), abdominal pain (one), and nausea (one). There was no discernable pattern of AEs with increasing dose. Four subjects experienced an AE that was considered to be related to SBI during the placebo-controlled, double-blind, 2-day, crossover phase; one in the 5 g SBI group (diarrhea and abdominal pain) and three subjects in the 20 g SBI group (flatulence and bloating). During the 14-day open-label phase, six subjects experienced an AE that was considered to be related to SBI: four subjects in the SBI 2.5 g BID group (abdominal cramps, constipation, bloating, and diarrhea) and two subjects in the SBI 10 g BID group (abdominal cramps, constipation, and nausea). Two subjects withdrew from the study due to an AE. Both subjects were in the SBI 5.0 g group: one discontinued due to abdominal cramps (subject 014-0002) and the other discontinued due to abdominal cramps, bloating, and diarrhea (subject 014-0012).

Of the 42 subjects (comprising a total of 205 plasma samples), only a single subject (subject 014-0002) showed plasma levels of bovine IgG above the LOQ (4.6 ng/mL). In that one subject, there were two plasma samples (time 0 minute and 90 minutes) following the administration of placebo on day 2 that showed quantifiable amounts of bovine IgG (25 ng/mL and 254 ng/mL, respectively). No detectable levels of plasma bovine IgG were found at time 0 minute and 90 minutes following the administration of 5 g of SBI on day 1 or on day 9 following 6 additional days of dosing for this subject.

For the other 41 subjects, no quantifiable levels of bovine IgG levels were determined in plasma samples 90 minutes following the administration of a single dose of SBI on day 1 and day 2 or following multiple doses of SBI for up to 14 days.

Discussion
==========

Early studies evaluating the oral administration of bovine serum or plasma protein preparations in experimentally challenged or weaning animals have consistently reported dramatic improvements in growth, food intake, and overall health status when compared to animals fed control diets.[@b3-ceg-9-365],[@b13-ceg-9-365] SBI is one such preparation that is rich in immunoglobulin content, particularly the IgG class. Recent studies of SBI in human beings have yielded similar results of efficacy in the finished product, which is currently available as a medical food[@b9-ceg-9-365] and intended for conditions such as IBS-D,[@b10-ceg-9-365] IBD,[@b9-ceg-9-365] and HIV-associated enteropathy.[@b11-ceg-9-365] Indeed, in multiple clinical reports, the product has been shown to manage effectively the chronic loose and frequent stools found in these conditions,[@b10-ceg-9-365],[@b11-ceg-9-365],[@b14-ceg-9-365]--[@b16-ceg-9-365] as well as to improve nutritional outcomes in pediatric malnutrition.[@b17-ceg-9-365],[@b18-ceg-9-365]

The safety record of SBI is documented in the AE profile from those clinical studies, as well as the 22,000 or more patients that have ingested nearly 3 million doses of the commercial product, EnteraGam. It is important, nonetheless, to determine whether intact bovine protein, following oral administration, is capable of crossing the intestinal epithelium into the systemic circulation. In addition, demonstration of the survivability of immunoglobulins such as IgG throughout the entirety of the digestive tract would help to explain the positive results observed in patients with both small and large bowel disorders.

The current study evaluated the safety of SBI in normal, healthy adult volunteers as well as the absorption of amino acids from its constitutive protein. Subjects ingested a single dose of placebo or SBI at one of the three dose levels during the randomized, double-blind, crossover phase and continued on SBI BID for an additional 2 weeks. Plasma samples were collected for evaluating changes in amino acid levels following oral administration of SBI and for examining the potential for bovine IgG to appear in the systemic circulation. Bovine IgG surviving the transit through the digestive tract was determined from stool samples.

Following the administration of SBI, a significant dose-dependent increase in the plasma AUC was observed for both total and essential amino acids. This finding was not surprising given the composition of SBI is \~95% protein (w/w), which includes ≥50% IgG.[@b19-ceg-9-365] Since IgG is inherently resistant to proteolytic digestion, it is plausible that \~40% nonimmunoglobulin protein fraction of SBI was responsible for the majority of the increase in total amino acid levels that we observed.[@b5-ceg-9-365],[@b8-ceg-9-365] Inspection of the time course for the increase in amino acid levels in plasma showed delayed absorption (both total and essential amino acids) in the 20 g group in which peak concentrations appeared 90--120 minutes post dosing, as compared to the 5 g and 10 g groups, where peak levels occurred \~30--45 minutes. A few factors may have played a role in the delayed absorption: 1) the rate of gastric digestion and emptying which may be influenced by the volume and composition of the protein ingested and/or 2) a high concentration of amino acids may have saturated the transport system across the epithelial membrane.

Although significant digestion of the protein content of SBI occurred in these healthy subjects, which was consistent with previously reported results in other studies (detection of bovine IgG in fecal samples from human children or adults following oral administration of bovine plasma or colostrum preparations[@b5-ceg-9-365]--[@b7-ceg-9-365],[@b20-ceg-9-365]--[@b22-ceg-9-365]), bovine IgG was detected in the stool from subjects on day 9 and day 16. A recent review of human studies in infants, children, and adults also reported that 12 of the 15 studies demonstrated that orally administered IgG derived from human or bovine serum, or bovine milk or colostrum, survives gastric exposure and resists proteolytic digestion in the stomach and the intestinal tract.[@b8-ceg-9-365] Collectively, these studies demonstrate that a portion of bovine IgG survives GI transit following oral administration of protein fractions prepared from bovine serum, plasma, or colostrum. It is believed that the IgG fraction of SBI is responsible for the observed effects in patients with intestinal disorders, which is supported by the abovementioned observation that a specific amount of this class of immunoglobulins in SBI survives transit through the entirety of the GI tract. The extent of degradation of immunoglobulins within healthy volunteers versus patients with GI disorders is dictated by several factors that include not only the conditions present throughout the GI tract but also transit time and the intrinsic stability of the immunoglobulin proteins themselves.

This study is the first to evaluate in human beings the safety of SBI at multiple dose levels ranging as high as 20 g/day. Several previous studies were conducted to evaluate the clinical benefits and/or safety of bovine immunoglobulin preparations in human infants,[@b23-ceg-9-365],[@b24-ceg-9-365] children,[@b17-ceg-9-365],[@b18-ceg-9-365],[@b20-ceg-9-365] and adults.[@b5-ceg-9-365],[@b7-ceg-9-365],[@b21-ceg-9-365] In the current study, all the AEs reported were mild or moderate in intensity and were associated with some type of GI symptom. Only two subjects withdrew from the study due to AEs, and there were no SAEs reported. These results confirm and extend the findings of other studies regarding the safety of bovine immunoglobulin preparations[@b17-ceg-9-365],[@b18-ceg-9-365] and further document the safety of SBI at dose levels as high as 20 g/day.

Using our test method, we were unable to detect quantifiable levels of bovine IgG in plasma samples obtained from subjects 90 minutes after a single dose of SBI, or in plasma samples from subjects on day 16 after multiple daily doses of SBI. One subject showed quantifiable levels of plasma bovine IgG on day 2, both prior to and 90 minutes after receiving placebo. This subject received SBI on day 1, but it is unlikely that the bovine IgG detected in plasma on day 2 was from the dose of SBI (5 g once daily \[QD\]) received on day 1, since transit through the small intestine is typically completed by 6 hours in most individuals.[@b25-ceg-9-365] In addition, it is highly unlikely that the bovine IgG from a single dose of SBI would appear and increase 10-fold in plasma during a narrow, 90-minute observation window 24 hours after ingestion. Furthermore, bovine IgG was not detected in plasma from 20 other subjects on day 2 after having received SBI on day 1 (5 g QD, 10 g QD, or 20 g QD) or in plasma samples from any subject on day 16 after receiving multiple daily doses of SBI. Collectively, these observations suggest that the detection of plasma IgG in the single subject described earlier is most likely due to mishandling of the plasma sample or some unknown substance in the plasma sample that confounded assay results.

The immunoglobulins found in SBI have been shown to bind in vitro to many different microbial components, which is believed to provide the basis for the mechanism in which SBI imparts its benefits. Indeed, SBI binding has been confirmed for lipopolysaccharide, peptidoglycan, flagellin, and a number of other microbial antigens that could traverse a damaged intestinal barrier and cause activation of the intestinal immune system and disrupt immune balance and gut barrier function.[@b19-ceg-9-365],[@b26-ceg-9-365],[@b27-ceg-9-365] While the mechanism of action of SBI has not been fully elucidated, the binding of antigens capable of inducing inflammation may prevent their passage into the lamina propria, thereby dampening potential immune responses in the gut-associated lymphoid tissue involved in disrupting intestinal homeostasis. Results from studies employing animal models of colitis have also provided results that are consistent with the hypothesis that SBI helps support intestinal homeostasis.[@b28-ceg-9-365],[@b29-ceg-9-365]

It is also possible that other nutritive components in SBI are additive to or act synergistically with the activity of bovine IgG. For example, nutritional studies have shown that dietary supplementation with several amino acids (eg, arginine, glutamine, glutamate, leucine, and proline) modulate gene expression, enhance growth of the small intestine and skeletal muscle, and benefit immune cells.[@b30-ceg-9-365],[@b31-ceg-9-365] Such studies have led to the designation of these amino acids as "conditionally essential" during certain physiologic and pathologic conditions.[@b31-ceg-9-365],[@b32-ceg-9-365] It has also been reported that increased tryptophan catabolism through the kynurenine pathway, by indoleamine 2,3-dioxygenase-1 expressed by activated dendritic cells and monocytes or other enzymes associated with the intestinal microbiota,[@b33-ceg-9-365] is associated with impaired differentiation and activity of T-cells,[@b34-ceg-9-365],[@b35-ceg-9-365] which may contribute to further gut barrier dysfunction, alterations in the gut microbiota, and immune activation that persist in states of intestinal disorders. This article also reports statistically significant increases in levels of tryptophan in plasma of subjects after consuming SBI, which possibly acts in combination with IgG to provide immune and gut barrier benefits observed in other studies.[@b10-ceg-9-365],[@b11-ceg-9-365]

Conclusion
==========

Collectively, the findings in this study demonstrate that oral administration of SBI (EnteraGam) is safe at levels at least as high as 20 g/day and leads to increases in plasma essential amino acids with no appearance of bovine IgG in plasma. Our results also demonstrate levels of bovine IgG in stool samples, suggesting at least partial survival of IgG during transit through the GI tract in healthy volunteers.
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![Study design and schedule of procedures.\
**Notes:** A screening period was followed by study visits on days 1, 2, 9 and 16. Triangles indicate the days on which study end points were assessed (except in the case of physical examinations that were symptom-directed after screening). Plasma samples were collected for amino acid analysis at time 0 minute and at 15 minutes, 30 minutes, 45 minutes, 60 minutes, 90 minutes, 120 minutes, and 180 minutes after administration of the investigational product on days 1 and 2. Plasma for bovine IgG assessment was collected at time 0 minute and 90 minutes after administration of the investigational product on days 1 and 2 and once on day 16. Stool samples for bovine IgG assessments were collected on days 1, 9 and 16. \*At least 8-hour fast prior to dosing.\
**Abbreviation:** IgG, immunoglobulin G.](ceg-9-365Fig1){#f1-ceg-9-365}

![AUC~0--180~ (nmol/mL×min) following ingestion of SBI at 5 g, 10 g, or 20 g dose levels (LS mean adjusted for levels from matching placebo dose \[test minus placebo\] using a mixed model for crossover data) for total amino acids (**A**), essential amino acids (**B**), and tryptophan (**C**).\
**Note:** \**p*\<0.02 versus placebo at matching dose level.\
**Abbreviations:** AUC~0--180~, area under the plasma amino acid concentration--time curve from time 0 to 180 minutes; EAA, essential amino acids; LS, least square; SBI, serum-derived bovine immunoglobulin/protein isolate; TAA, total amino acids; Trp, tryptophan.](ceg-9-365Fig2){#f2-ceg-9-365}

![Mean plasma amino acid concentration-time curves for total amino acids (**A**), essential amino acids (**B**), and tryptophan (**C**) during a 3-hour post-ingestion period after a single dose of 5 g, 10 g, or 20 g of SBI or placebo.\
**Abbreviations:** EAA, essential amino acids; QD, once daily; SBI, serum-derived bovine immunoglobulin/protein isolate; TAA, total amino acids; Trp, tryptophan.](ceg-9-365Fig3){#f3-ceg-9-365}

###### 

Amino acid composition of proteins within SBI

  Amino acid                 Mean ± SD (mg)[\*](#tfn1-ceg-9-365){ref-type="table-fn"}
  -------------------------- ----------------------------------------------------------
  Alanine                    204.1±1.2
  Arginine                   236.4±0.6
  Asparagine/aspartic acid   417.8±3.7
  Cystine                    107.0±2.4
  Glutamine/glutamic acid    512.8±3.3
  Glycine                    191.4±0.3
  Histidine                  111.2±0.8
  Isoleucine                 138.9±0.6
  Leucine                    367.8±0.9
  Lysine                     320.8±3.4
  Methionine                 47.3±1.2
  Phenylalanine              206.5±1.4
  Proline                    265.3±2.1
  Serine                     414.2±5.6
  Threonine                  360.5±2.7
  Tryptophan                 94.0±2.0
  Tyrosine                   241.3±0.7
  Valine                     373.5±3.3

**Notes:**

Represents the amount of amino acid (mg; mean +/− SD) contained in 5 g of SBI, as determined from quantitative testing of seven manufacturing lots.

**Abbreviations:** SBI, serum-derived bovine immunoglobulin/protein isolate; SD, standard deviation.

###### 

Disposition of study subjects

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Description                                                Placebo-controlled, double-blind, crossover phase\   Open-label phase\   Overall\                                                                                                         
                                                             (Day 1 and day 2)                                    (Days 3--16)        (Days 1--16)                                                                                                     
  ---------------------------------------------------------- ---------------------------------------------------- ------------------- ---------------------------------------------- ------------------------------------------------- ------- ------- ----------------------------------------------
  Subjects participating in the study                        18                                                   12                  12                                             14                                                14      13      42

  Subjects completing 2-day double-blind, crossover period   18                                                   12                  11[\*](#tfn4-ceg-9-365){ref-type="table-fn"}   --                                                --      --      41[\*](#tfn4-ceg-9-365){ref-type="table-fn"}

  Subjects completing 14-day open-label period               --                                                   --                  --                                             12[\#](#tfn5-ceg-9-365){ref-type="table-fn"}/14   14/14   13/13   39/41

  Subjects completing:                                                                                                                                                                                                                                 

   Plasma amino acid analysis                                18                                                   12                  11                                             --                                                --      --      41

   Plasma IgG evaluation                                     18                                                   12                  11                                             14                                                14      13      41

   Stool IgG evaluation                                      --                                                   --                  --                                             7                                                 7       7       21[‡](#tfn6-ceg-9-365){ref-type="table-fn"}
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** Dosing errors occurred in six subjects during the double-blind, crossover phase. Four subjects assigned to 10 g of SBI received 5 g of SBI and two subjects assigned to 20 g of SBI received 10 g of SBI. These six subjects continued with the assigned dose of SBI during the 14-day, open-label phase of the study. An additional six subjects were added to the 2-day, double-blind, crossover phase.

One subject withdrew consent on day 1 after a single placebo dose; therefore, only 41 of 42 subjects received crossover dose of SBI on day 2.

Two subjects withdrew during the open-label phase due to AEs.

Stool IgG analysis was conducted only on subjects who provided a baseline stool sample prior to receiving an active dose of SBI.

**Abbreviations:** AE, adverse event; BID, twice daily; IgG, immunoglobulin G; QD, once daily; SBI, serum-derived bovine immunoglobulin/protein isolate.

###### 

Baseline demographics

  Description                  SBI 5.0 g QD; N (%)   SBI 10.0 g QD; N (%)   SBI 20.0 g QD; N (%)   All groups; N (%)
  ---------------------------- --------------------- ---------------------- ---------------------- -------------------
  Total subjects               18 (100)              12 (100)               12 (100)               42 (100)
  Sex                                                                                              
   Female                      10 (56)               6 (50)                 7 (58)                 23 (55)
   Male                        8 (44)                6 (50)                 5 (42)                 19 (45)
  Race                                                                                             
   White                       7 (39)                9 (75)                 9 (75)                 25 (59)
   Black or African American   10 (56)               3 (25)                 2 (17)                 15 (36)
   Asian                       1 (6)                 0 (0)                  1 (8)                  2 (5)
  Ethnicity                                                                                        
   Non-Hispanic/Latino         17 (94)               12 (100)               12 (100)               41 (98)
   Hispanic/Latino             1 (6)                 0 (0)                  0 (0)                  1 (2)
  Age (years)                                                                                      
   Mean ± SD                   37.3±9.66             45.0±16.64             39.9±13.26             40.2±13.06
   Median                      34.5                  39.0                   39.0                   38.0
   Minimum--maximum            24--56                27--69                 18--58                 18--69

**Abbreviations:** QD, once daily; SBI, serum-derived bovine immunoglobulin/protein isolate; SD, standard deviation.

###### 

Adverse events

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Safety population[\*](#tfn9-ceg-9-365){ref-type="table-fn"}                            Placebo-controlled, double-blind, crossover phase\   Open-label phase\   Overall\                       
                                                                                         (Day 1 and day 2)                                    (Days 3--16)        (Days 1--16)                   
  -------------------------------------------------------------------------------------- ---------------------------------------------------- ------------------- -------------- --- --- --- --- ----
  Number of subjects with at least one TEAE[\#](#tfn10-ceg-9-365){ref-type="table-fn"}   1                                                    4                   0              3   7   5   5   20

  TEAEs by maximum severity                                                                                                                                                                      

   Mild                                                                                  1                                                    1                   0              3   4   3   3   13

   Moderate                                                                              0                                                    3                   0              1   4   2   3   11

   Severe                                                                                0                                                    0                   0              0   0   0   0   0

  SAEs                                                                                   0                                                    0                   0              0   0   0   0   0

  Number of subjects with one or more TEAEs related to nutritional therapy               0                                                    1                   0              3   4   0   2   8

   Abdominal cramps                                                                      0                                                    0                   0              0   3   0   1   4

   Constipation                                                                          0                                                    0                   0              0   2   0   1   3

   Bloating                                                                              0                                                    0                   0              1   1   0   0   2

   Diarrhea                                                                              0                                                    1                   0              0   1   0   0   2

   Flatulence                                                                            0                                                    0                   0              2   0   0   0   2

   Abdominal pain                                                                        0                                                    1                   0              0   0   0   0   1

   Nausea                                                                                0                                                    0                   0              0   0   0   1   1
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Safety analysis set consisted of all randomized subjects who received at least one dose of double-blind investigational nutritional therapy.

Figures in the table refer to the number of subjects experiencing one or more AEs. Multiple AEs within the same preferred term or system organ class that were experienced by the same subject were counted only once. Subjects that experienced an AE on Day 1 and another AE on day 2 of the placebo-controlled phase were counted only once in the overall total.

**Abbreviations:** AE, adverse event; BID, twice daily; QD, once daily; SAE, serious AE; SBI, serum-derived bovine immunoglobulin/protein isolate; TEAE, therapy-emergent AE.
